- Home
- HRMY vs HG Comparison
HRMY vs HG Comparison
Compare HRMY & HG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HRMY | HG |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.8B |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | HRMY | HG |
|---|---|---|
| Price | $38.44 | $28.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $51.33 | $29.00 |
| AVG Volume (30 Days) | ★ 775.4K | 478.8K |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.44 | N/A |
| EPS | 3.17 | ★ 4.19 |
| Revenue | $825,944,000.00 | ★ $2,745,461,000.00 |
| Revenue This Year | $23.11 | $25.41 |
| Revenue Next Year | $16.15 | $0.82 |
| P/E Ratio | $12.27 | ★ $6.78 |
| Revenue Growth | ★ 21.13 | 21.12 |
| 52 Week Low | $25.52 | $16.80 |
| 52 Week High | $40.93 | $28.70 |
Technical Indicators
Market Signals| Indicator | HRMY | HG |
|---|---|---|
| Relative Strength Index (RSI) | 59.66 | 66.27 |
| Support Level | $37.12 | $27.45 |
| Resistance Level | $40.87 | $28.70 |
| Average True Range (ATR) | 1.42 | 0.56 |
| MACD | -0.32 | 0.04 |
| Stochastic Oscillator | 39.35 | 90.32 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About HG Hamilton Insurance Group Ltd. Class B
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.